Investor Relations

Press Release

View printer-friendly version

<<  Back

Vital Therapies Announces Upcoming First Quarter Financial Results Conference Call With Webcast

SAN DIEGO, May 02, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its first quarter 2017 financial results after the market closes on Tuesday, May 9, 2017. The press release will be followed by a conference call on Wednesday, May 10, 2017 at 4:30 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review financial results and discuss other business matters.

The conference call dial-in numbers are (855) 765-5682 for domestic callers and (919) 825-3204 for international callers. The conference ID number for the call is 14568675. Participants may access the live webcast via a link on the Vital Therapies website in the Investors Relations section under Events at: http://ir.vitaltherapies.com/. The webcast will be archived on the Company's website shortly after completion of the call.

For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 7:30 p.m. ET on May 10, 2017 to 7:30 p.m. ET on May 17, 2017. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 14568675. 

About Vital Therapies, Inc.

Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure. The Company's ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.

Contact:

Vital Therapies, Inc. 
Al Kildani
Vice President, Investor Relations and Business Development
858-673-6840
akildani@vitaltherapies.com